From pleasure to pain? Ecstasy and heart failure

    Tuesday, October 25, 1:30 p.m., Los Angeles Convention Center Exhibit Hall, Poster 516

    A medical student from Abington Jefferson Health in Abington, Pennsylvania, will present a case of methamphetamine-induced acute coronary syndrome. A 22-year-old man was brought to the emergency department (ED) for an evaluation of acute onset shortness of breath and chest pain. The patient reported he had taken “ecstasy” (“Molly”, MDMA) six hours before coming to the ED.



    LOS ANGELES (October 17, 2016)– According to the Cystic Fibrosis Foundation Patient Registry, more than 70,000 people worldwide are suffering from the disease, with approximately 1,000 new cases diagnosed each year in the United States alone. Adherence to inhaled and oral therapies for cystic fibrosis patients is discouragingly low, ranging 31-35 percent for inhaled antibiotics. Programs to enhance adherence have had mixed success; a new pilot study from Ventura County Medical Center in Ventura, California, shows remarkable improvement in adherence using Bluetooth technology.


    World Lung Cancer Day commemorates, celebrates and supports those impacted by lung cancer

    GLENVIEW, Ill.  (July 29, 2016) – On World Lung Cancer Day on 1 August, the Forum of International Respiratory Societies (FIRS) and its members celebrate and support those impacted by lung cancer. FIRS joins the grassroots efforts of the lung cancer community to raise awareness about lung cancer and its global impact, creating an educational movement of understanding lung cancer risks as well as early treatment around the world.


    LOS ANGELES (October 17, 2016) – A study from Gundersen Health System, La Crosse, Wisconsin, reveals to the value of blood-based genomic and proteomic testing in patients with lung cancer at the time of initial diagnoses. Non-small cell lung cancer (NSCLC) refers to a group of cancers that share common characteristics but have different genetic features that make them more or less responsive to specific treatments. In this study, genomic and proteomic testing of blood specimens rapidly identified genetic mutations that determined optimal, personalized treatment. Compared with testing of biopsy specimens, the blood tests yielded both important diagnostic information much faster (within 72 hours) regardless of disease stage, and significantly decreasing the wait period between diagnoses and the start of treatment.


    INVESTMENT AND ACTION NEEDED TO END TB

    Cape Town, Glenview, Lausanne, Montevideo, New York, Paris, Tokyo, March 24, 2016 -In support of World TB Day, 24 March, the Forum of International Respiratory Societies (FIRS) calls for united efforts to mobilise the financial and human resources to end tuberculosis (TB).


    Page 11 of 14

    © 2019 FIRS All Rights Reserved.
    Website design by ERS